BACKGROUND: In the two European Union (EU)-funded projects, PCM4EU (Personalized Cancer Medicine for all EU citizens) and PRIME-ROSE (Precision Cancer Medicine Repurposing System Using Pragmatic Clinical Trials), we aim to facilitate implementation of precision cancer medicine (PCM) in Europe by leveraging the experience from ongoing national initiatives that have already been particularly successful. PATIENTS AND METHODS: PCM4EU and PRIME-ROSE gather 17 and 24 partners, respectively, from 19 European countries. The projects are based on a network of Drug Rediscovery Protocol (DRUP)-like clinical trials that are currently ongoing or soon to start in 11 different countries, and with more trials expected to be established soon. The main aims of both the projects are to improve implementation pathways from molecular diagnostics to treatment, and reimbursement of diagnostics and tumour-tailored therapies to provide examples of best practices for PCM in Europe. RESULTS: PCM4EU and PRIME-ROSE were launched in January and July 2023, respectively. Educational materials, including a podcast series, are already available from the PCM4EU website (http://www.pcm4eu.eu). The first reports, including an overview of requirements for the reimbursement systems in participating countries and a guide on patient involvement, are expected to be published in 2024. CONCLUSION: PCM4EU and PRIME-ROSE were launched in January and July 2023, respectively. Educational materials, including a podcast series, are already available from the PCM4EU website (http://www.pcm4eu.eu). The first reports, including an overview of requirements for the reimbursement systems in participating countries and a guide on patient involvement, are expected to be published in 2024. CONCLUSION: European collaboration can facilitate the implementation of PCM and thereby provide affordable and equitable access to precision diagnostics and matched therapies for more patients.

Centre Léon Bérard Lyon France

Clinical Trial Unit Comprehensive Cancer Centre Helsinki University Hospital Helsinki Finland

Department of Clinical Genetics Pathology and Molecular Diagnostics Region Skåne Malmö Sweden

Department of Medical Oncology Erasmus MC Cancer Institute Rotterdam The Netherlands

Department of Medical Oncology Leiden University Medical Centre Leiden The Netherlands

Department of Medical Oncology Leiden University Medical Centre Leiden The Netherlands; CZ Health Insurance Tilburg The Netherlands

Department of Molecular Oncology and Immunology Netherlands Cancer Institute Amsterdam The Netherlands

Department of Oncology Institute of Clinical Sciences Sahlgrenska Academy at University of Gothenburg Gothenburg Sweden; Department of Oncology Sahlgrenska University Hospital Gothenburg Sweden

Department of Oncology Rigshospitalet Copenhagen University Hospital Copenhagen Denmark

Division of Cancer Sciences The University of Manchester and The Christie NHS Foundation Trust Manchester UK

Hematology Oncology Clinic at Tartu University Hospital Tartu Estonia

Institute for Cancer Research Oslo University Hospital and Institute of Clinical Medicine University of Oslo Oslo Norway

Institute for Cancer Research Oslo University Hospital and Institute of Clinical Medicine University of Oslo Oslo Norway; Department of Pathology Oslo University Hospital Oslo Norway

Institute for Cancer Research Oslo University Hospital and Institute of Clinical Medicine University of Oslo Oslo Norway; Division of Cancer Medicine Oslo University Hospital Oslo Norway

Instituto Português de Oncologia do Porto FG Porto Portugal

Maria Sklodowska Curie Institute of Oncology Warsaw Poland

Oslo Centre for Biostatistics and Epidemiology Oslo University Hospital Oslo Norway

Stockholm School of Economics Institute for Research Stockholm Sweden

Swedish Institute for Health Economics Lund Sweden

Trinity St James Cancer Institute Trinity College Dublin Ireland

See more in PubMed

Hoes LR, van Berge Henegouwen JM, van der Wijngaart H, Zeverijn LJ, van der Velden DL, van de Haar Jet al. . Patients with rare cancers in the Drug Rediscovery Protocol (DRUP) benefit from genomics-guided treatment. Clin Cancer Res. 2022. Apr 1;28(7):1402–1411. 10.1158/1078-0432.CCR-21-3752 PubMed DOI PMC

Andre F, Filleron T, Kamal M, Mosele F, Arnedos M, Dalenc Fet al. . Genomics to select treatment for patients with metastatic breast cancer. Nature. 2022. Oct;610(7931):343–348. 10.1038/s41586-022-05068-3 PubMed DOI

Leary A, Besse B, André F. The need for pragmatic, affordable, and practice-changing real-life clinical trials in oncology. Lancet. 2023;403(10424):406-408. 10.1016/S0140-6736(23)02199-2 PubMed DOI

van der Velden DL, Hoes LR, van der Wijngaart H, van Berge Henegouwen JM, van Werkhoven E, Roepman Pet al. . The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs. Nature. 2019;574(7776):127–131. 10.1038/s41586-019-1600-x PubMed DOI

Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg Tet al. . Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway. J Transl Med. 2022;20(1): 317. 10.1186/s12967-022-03432-5 PubMed DOI PMC

Kringelbach T, Højgaard M, Rohrberg K, Spanggaard I, Laursen BE, Ladekarl Met al. . ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling – a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial. BMC Cancer. 2023. Feb 22;23(1):182. 10.1186/s12885-023-10632-9 PubMed DOI PMC

Mangat PK, Halabi S, Bruinooge SS, Garrett-Mayer E, Alva A, Janeway KAet al. . Rationale and design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2018;2018:10.1200. 10.1200/PO.18.00122 PubMed DOI PMC

Skamene T, Siu L, Renouf D, Laskin J, Bedard P, Jones Set al. . Canadian profiling and targeted agent utilisation trial (CAPTUR/PM.1): a phase II basket precision medicine trial. J Clin Oncol. 2018:36(15-suppl): TPS12127. 10.1200/JCO.2018.36.15_suppl.TPS12127 DOI

Zeverijn LJ, Looze EJ, Thavaneswaran S, van Berge Henegouwen JM, Simes RJ, Hoes LRet al. . Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials. Int J Cancer. 2023. Oct 1;153(7):1413–1422. 10.1200/JCO.2023.41.16_suppl.3101 PubMed DOI

van der Wijngaart H, Hoes LR, van Berge Henegouwen JM, van der Velden DL, Zeverijn LJ, Roepman Pet al. . Patients with Biallelic BRCA1/2 inactivation respond to olaparib treatment across histologic tumor types. Clin Cancer Res. 2021;27(22):6106–6114. 10.1158/1078-0432.CCR-21-1104 PubMed DOI

van Waalwijk van Doorn-Khosrovani SB, Pisters-van Roy A, van Saase L, van der Graaff M, Gijzen J, Sleijfer Set al. . Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients. Ann Oncol. 2019;30(5):663–665. 10.1093/annonc/mdz119 PubMed DOI

Rosenquist R, Edsjö A, Russnes H, Lethiö J, Tamborero D, Hovig Eet al. . High-throughput molecular assays for inclusion in personalised oncology trials – state-of-the-art and beyond. J Intern Med. 2024. Jun;295(6):785-803. 10.1111/joim.13785 PubMed DOI

Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas Net al. . A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol. 2018. Sep 1;29(9):1895–1902. 10.1093/annonc/mdy263 PubMed DOI PMC

Zeverijn LJ, van Waalwijk van Doorn-Khosrovani SB, van Roy AAMGP, Timmers L, Ly Tran TH, de Boer JEet al. . Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform. Lancet Oncol. 2022. Feb;23(2):198–201. 10.1016/S1470-2045(21)00707-5 PubMed DOI

Taskén K, Russnes HEG, Aas E, Bjørge L, Blix ES; CONNECT Public–Private Partnership Consortium. et al. . A national precision cancer medicine implementation initiative for Norway. Nat Med. 2022. May;28(5):885–887. PubMed

Steen K, van Bueren E. Urban living labs: a living lab way of working. 2017: pp1-96. (publ Amsterdam Institute for Advanced Metropolitan Solutions and Delft University of Technology, Amsterdam, The Netherlands: ) https://www.ams-institute.org/documents/28/AMS_Living_Lab_Way_of_Working-ed4.pdf